<DOC>
	<DOCNO>NCT01748851</DOCNO>
	<brief_summary>The purpose study identify non-inferiority combination therapy Capecitabine Oxaliplatin compare combination therapy Fluorouracil/Folinic acid Oxaliplatin patient advance gastric cancer .</brief_summary>
	<brief_title>XELOX Versus FOLFOX Advanced Gastric Cancer ( AGC )</brief_title>
	<detailed_description>Quality assurance : Data collect , control , monitor Korean Clinical Study Group ( KCSG ) data center . Data enter throuGh E-Case report form ( CRF ) ( Web base data input ) Korean Clinical Study Group ( KCSG ) data center standard Operating Procedures address registry operation analysis activity , patient recruitment , data collection , data management , data analysis , report adverse event , change management Sample size assessment specify number participant participant year consult Statistical specialist . And data analysis also discuss Expected median progression-free survival ( PFS ) Xelox : 6 month total number event require : 359 197 patient need After 10 % follow-up loss , 219 patient arm , total 438 patient enrol</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Age : old 20 2 . A patient least one measurable primary lesion diameter confirm 10mm Spiral CT multidetector CT ( MD CT ) , 20 mm longer conventional CT ( use consistent method study period ) . ( RECIST v1.1 ) *but , patient measureable lesion metastatic resect M1 lymph node bone metastasis ascites could enrol . 3 . No prior palliative chemotherapy ( relapse 1 year later end adjuvant treatment available ) 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 5 . The following laboratory test result : ① absolute neutrophil count ( ANC ) ≥1,500/micro Liter ( uL ) , Platelet ≥ 100,000/uL , ② aspartate aminotransferase ( AST ) ≤ 3 x Upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) ≤ 3 x ULN , Total bilirubin ≤ 2.0 mg/dL ( case liver metastasis , 5 x ULN AST , ALT ) ③ Creatinine ≤ 1.5 mg/dL 6 . A patient sign informed consent prior participation study understand he/she right withdrawal participation study time without disadvantage . 1 . HER2 Positive patient 2 . Any malignancy within past 2 year except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri 3 . Subjects receive radiotherapy within 4 week prior randomization 4 . Subjects chronic acute infection need treatment 5 . Subjects receive major operation within 4 week prior randomization 6. patient clinically significant ( i.e . active ) heart disease ( e.g . congestive heart failure , symptomatic coronary artery disease , cardiac arrhythmia , etc ) myocardial infarction within past 12 month . 7. patient epilepsy psychiatric problem include central nervous system ( CNS ) metastasis . 8 . Subjects able ingestion malabsorption disorder 9. peripheral neuropathy accompany functional loss 10 . Prior history allergic reaction study treatment drug 11 . A patient history clinical trial within 4 week 12 . A patient childbearing potential without tested pregnancy baseline positive . ( A postmenopausal woman amenorrhea period least 12 month longer consider nonchildbearing potential . ) 13. subject decide investigator decide exclusion reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>